Virinchi to acquire Bristlecone Hospitals business from subsidiary for Rs 100 Cr

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

VIRINCHI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹15.40

prior close

₹15.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.4%+3.6% vs market

Software Products peers, median of 36sector+0.9%+4.1% vs sector

On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 4.1 pts more than its Software Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.8

10m

+3.8

15m

+2.9

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9+1.4+3.6+0.9+4.1

Next day

+3.9+1.5+2.4+0.6+3.3

+3.2+0.5+2.7+0.2+3.0

+1.6+1.1+0.4+0.5+1.1

+0.1+0.7-0.5-0.3+0.4

+0.6-0.4+1.1-2.2+2.8

+2.5+0.5+1.9-2.3+4.8

15d

-0.1+0.1-0.1-2.8+2.7

+1.3+3.5-2.2-4.0+5.3

-7.7+5.8-13.5-3.7-4.0

-15.6+2.4-18.0-1.5-14.0

UpDownMarket · Nifty Microcap 250Sector · Software Products peers, median of 36Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved acquiring Bristlecone Hospitals (Primary and Secondary care) business from material subsidiary VHCPL on slump sale basis for Rs 100 Crores, effective April 1, 2026. VHCPL turnover was Rs 133 Cr, Rs 104 Cr and Rs 83 Cr over the last three years. Loans to VHCPL will be adjusted against consideration; no new shares issued. Related party transaction needing shareholder approval via postal ballot.

Likely market impact

Consolidates healthcare business under the listed entity. Streamlines structure for AI-led expansion but is a related party deal needing shareholder approval.